A Phase II, Randomized, Double-blinded, Placebo-controlled Trial of Liraglutide in Parkinson's Disease
Latest Information Update: 11 Mar 2024
At a glance
- Drugs Liraglutide (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- 27 Oct 2022 Status changed from active, no longer recruiting to completed.
- 20 Oct 2021 Planned End Date changed from 1 Dec 2021 to 30 Jun 2022.
- 20 Oct 2021 Planned primary completion date changed from 1 Sep 2021 to 3 Apr 2022.